海珠喘息定片联合生物共振诊断治疗仪治疗支气管哮喘临床研究

目的 评价海珠喘息定片联合生物共振诊断治疗仪治疗支气管哮喘的疗效.方法 将符合入选标准的94例支气管哮喘患者采用随机数字表法分为2组,每组47例.对照组采用生物共振诊断治疗仪治疗,观察组在对照组基础上口服海珠喘息定片.2组均治疗50 d.采用全自动肺功能检测仪检测用力肺活量(forced vital capacity,FVC)、呼气峰流速值(peak expiratory flow,PEF)、第1秒用力呼气容积(forced expiratory volume in 1 second,FEV1)、FEV1/FVC;采用ELISA法检测血清hs-CRP、IL-8、IL-4、TNF-α含量,以及基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)、基质金属蛋白酶抑制剂-1(tissue inhibitors of metalloproteinase 1,TIMP-1)、Toll样受体2(toll like receptor 2,TLR2)及嗜酸性阳离子蛋白(eosinophil cationic protein,ECP)含量,评价临床疗效.结果 观察组总有效率为91.5%(43/47)、对照组为72.3%(34/47),2组比较差异有统计学意义(Z=4.201,P=0.037).治疗后,观察组FVC(2.45±0.37)L比(1.93±0.32)L,t=3.561]、PEF(6.16±1.25)L/s比(5.56±1.10)L/s,t=3.413]、FEV1/FVC(68.39±6.44)%比(62.31±5.97)%,t=3.315]及FEV1(2.61±0.56)L比(2.21±0.47)L,t=3.672]均高于对照组(P<0.05);观察组血清hs-CRP(8.14±0.42)mg/L比(12.41±0.65)mg/L,t=3.424]、IL-8(113.47±11.13)ng/L比(153.81±19.73)ng/L,t=3.692]、TNF-α(0.31±0.04)ng/L比(0.70±0.13)ng/L,t=3.923]、IL-4(39.43±6.23)ng/L比(47.75±8.23)ng/L,t=3.783]水平均低于对照组(P<0.05);观察组血清MMP-9(84.89±9.19)ng/ml比(113.35±11.35)ng/ml,t=3.671]、TIMP-1(91.53±8.78)ng/ml比(131.15±12.45)ng/ml,t=3.782]、ECP(19.43±1.33)ng/L比(25.75±2.13)ng/L,t=3.561]水平均低于对照组(P<0.05),TLR2(270.31±7.01)ng/L比(198.70±10.13)ng/L;t=3.871,P=0.038]含量高于对照组.结论 海珠喘息定片联合生物共振诊断治疗仪可效改善支气管哮喘患者的肺功能,降低炎性细胞因子水平,提高临床疗效.

Clinical effect ofHaizhu-Chuanxdingi tablet with MORA-super Bio-Resonance in bronchial asthma and its influence on the levels of serum MMP-9, TIMP-1, TLR2 and ECP in patients

Objective To explore the clinical effect of Haizhu-Chuanxidingtablet with MORA-super bio-resonance in bronchial asthma.Methods A total of 94 patients met the inclusion criteria in our hospital were divided control group and observe group by a random way, 47 in each group. The control group was treated with MORA-super bio-resonance while the treatment group withHaizhu-Chuanxiding tablet on the base of control group. The treatment time was 50 days in the 2 groups. After the treatment, the effects in the 2 groups were compared. Before and after the treatment, the levels of lung function (FVC, PEF, FEV1% and FEV1), inflammation index (hs-CRP, IL-8,TNF-α and IL-4), matrix metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase 1 (TIMP-1), toll like receptor 2 (TLR2) and eosinophil cationic protein (ECP) were detected in the 2 groups.Results After the treatment, the effect rate was 91.5% (43/47) in the observe group, significantly higher than 72.3% (34/47) in the control group (Z=4.201,P=0.037). After the treatment, the levels of FVC (2.45 ± 0.37 Lvs.1.93 ± 0.32 L,t=3.561), PEF(6.16 ± 1.25 L/svs. 5.56 ± 1.10 L/s,t=3.413), FEV1/FVC (68.39% ± 6.44%vs. 62.31% ± 5.97%,t=3.315) and FEV1 (2.61 ± 0.56 Lvs. 2.21 ± 0.47 L,t=3.672) in the observe group significantly higher than the control group (P<0.05). After the treatment, the levels of hs-CRP (8.14 ± 0.42 mg/Lvs. 12.41 ± 0.65 mg/L,t=3.424), IL-8 (113.47 ± 11.13 ng/Lvs. 153.81 ± 19.73 ng/L,t=3.692), TNF-α (0.31 ± 0.04 ng/Lvs. 0.70 ± 0.13 ng/L,t=3.923)], IL-4 (39.43 ± 6.23 ng/Lvs. 47.75 ± 8.23 ng/L, t=3.783) in the observe group significantly lower than the control group (P<0.05). After the treatment, the levels of MMP-9 (84.89 ± 9.19 ng/mlvs. 113.35 ± 11.35 ng/ml,t=3.671), TIMP-1 (91.53 ± 8.78 ng/mlvs. 131.15 ± 12.45 ng/ml,t=3.782), ECP (19.43 ± 1.33 ng/Lvs. 25.75 ± 2.13 ng/L,t=3.561) in the observe group significantly lower than the control group (P<0.05). The level of TLR2 (270.31 ± 7.01 ng/Lvs. 198.70 ± 10.13 ng/L;t=3.871,P=0.038) in the observe group significantly higher than the control group (P<0.05).ConclusionsHaizhu-Chuanxidingtablet with MORA-super bio-resonance in bronchial asthma showed a good effect on patients with bronchial asthma and could promote the inflammation and lung function in patients.